NCT03088176View on ClinicalTrials.gov

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

PHASE1UnknownINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 25, 2017

Primary Completion Date

November 30, 2020

Study Completion Date

June 30, 2021

Conditions
MelanomaBRAF Gene Mutation
Interventions
DRUG

Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil

Up to 4mL administered on C1D1 intratumorally

DRUG

Talimogene Laherparep 100 Mil Pfu/Ml 1Ml

Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter

DRUG

Dabrafenib

150mg PO qday

DRUG

Trametinib

2mg PO qday

Trial Locations (1)

38138

West Cancer Center, Germantown

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

University of Tennessee

OTHER

collaborator

Amgen

INDUSTRY

lead

West Cancer Center

OTHER